NCT06661044Completed
Understanding the Benefits of Dietary Fibre Supplementation in Patients With Prostate Cancer
Exploiting Human Microbiota-associated in Vivo Models for Mechanistic Studies to Understand the Benefits of Dietary Fibre Supplementation in Patients With Prostate Cancer
Source: ClinicalTrials.gov · Last updated 30 Apr 2026
Brief summary (registry, in English)
The digestive tract (large intestine) contains microorganisms that digest complex carbohydrates in food to produce chemical substances which are beneficial to human health. The population of these microorganisms in faeces (stool samples) could be used to diagnose the health status of a person and this can be changed with the use of antibiotics, diet, radiotherapy or infection. Dietary fibre supplements can help provide nutrients for the beneficial bacteria from the large intestine to produce useful chemicals that may delay growth or even shrink prostate cancer in patients. The investigators will feed mice diets containing several dietary fibres (including inulin, pectin and hemp hull) and also faeces from healthy male human volunteers over 60 years old to see what effect this has on the makeup of the bacteria in their gut and the resulting beneficial metabolites (chemicals). For this work, the research team need to obtain four to six fresh faecal samples on the same day, so that these can be mixed fresh and stored for use as faecal microbiota transplant (FMT) in the mice. The researchers will then test how altering the gut microorganisms with faeces and dietary fibre supplements can influence the growth of prostate cancer cell tumours in mice. The investigators expect to see an effect of the fibres in promoting beneficial bacteria and in shrinking the tumours. This work will allow the investigators to identify dietary fibres that could be used in nutritional therapies for management of prostate cancer patients in future.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 6 (actual)
- First submitted
- 24 Oct 2024
- Start date
- 15 Nov 2024
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- University of Aberdeen
- Diseases
- Prostate cancer
- NCT number
- NCT06661044
What you commit to
- Study type: Observational
- Participants enrolled: 6
- From 15 Nov 2024 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Antibiotic therapy within previous 3 months.
Other illness
- Living with cancer/on active cancer treatment.
- Active ulcerative colitis or Crohn's disease.
- Known HIV or Hepatitis B positive.
Other
- Diarrhoea from recent foreign travel.
- Working directly on specific study for which samples are required.
- Line managed or supervised by PI of study.
Who the study is looking for
- Men (biologically male) over 60 years old.
- Regularly pass a bowel motion at least daily.
- Able to attend the Rowett Institute for consent procedure and able to arrange delivery of fresh faecal sample to the Rowett Institute on the required study day.
Age in the registry: 60 years to - · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Aberdeen Coordinator of this site? Confirm its status | Aberdeen | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.